Novartis drug shows benefits for COPD patients with lung hyperinflation

Novartis has announced new clinical trial data that further underline the benefits that its drug Ultibro Breezhaler can deliver for people with chronic obstructive pulmonary disease (COPD).

Results from the recent CLAIM study have been published in the Lancet Respiratory Medicine journal, demonstrating that once-daily Ultibro Breezhaler treatment can significantly improve lung and cardiac function in COPD patients with lung hyperinflation compared to placebo.

It means the drug was able to meet its primary endpoint in the study, with the effects of the therapy translating into clinically-relevant patient benefits of improved health status and breathlessness.

CLAIM is the first study to investigate the effects of dual bronchodilation on cardiac function and lung hyperinflation, a common COPD-related trait that can affect patients' quality of life.

Shreeram Aradhye, chief medical officer and global head of medical affairs at Novartis Pharmaceuticals, said: "Lung hyperinflation is often associated with impaired cardiac function in patients with COPD. The publication of the CLAIM study is important for any COPD patient with signs of lung hyperinflation."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.